The mobilization of PBSC is generally safe but not completely risk free. Pulsipher 1 reported 0.6% of serious and unexpected adverse events (AEs) in unrelated donors of PBSC. A review of EBMT reported an incidence of 7.25 severe AEs per 10 000 donations; the cardiac events consisted of four cardiac arrests in the BM donor group and two myocardial infarctions in the peripheral blood (PB) donor group of a total of 51 400 donations. 2 We report a case of paroxysmal atrial fibrillation (PAF) in a female sibling donor who underwent PBSC apheresis (PBSCa). The donor, aged 50 years and weighing 55 kg, with an unremarkable medical history, was subjected to assessments in accordance with the standards SIMTI-GITMO and IBMDR for PBSC donors. 3, 4 Physical tests, electrolytes, thrombophilic screening, thyroid function, electrocardiography (ECG) with effort tolerance and echocardiography were normal. The serum human chorionic gonadotropin level was negative. G-CSF was administered at a dose of 10 mg/kg/day s.c. with minimal bone pain. The PBSC collection started from day þ 4, when the flow cytometric CD34 þ cell count in PB was more than 20 cells/mL. The procedure was carried out using COM. TEC. (Fresenius HEMO CARE) in 3 h and 50 min, during which 8028 mL of blood (2.11 blood volume) was processed. A total of 3 Â 10 6 CD34 þ /kg recipient weight was collected. A volume of 594 mL of acid citrate dextrose-A (ACD-A) was used during PBSCa. For the appearance of lip numbness, 1 fl Ca-gluconate was infused, which resulted in resolution of symptoms secondary to hypocalcemia. Monitoring of blood pressure and heart rhythm during and after the procedure were normal. Laboratory investigations performed 3 h after the end of the procedure (Table 1) showed hypokalemia (K þ ¼ 2.9 mEq/L, normal range: 3.5 and 5.0 mEq/L). The donor was discharged from the Day Hospital with indication to take potassium chloride orally at a dose of 1200 mg two times daily and monitoring of serum potassium levels the following day. However, about 10 h after the end of PBSCa, the donor showed an episode of micturition syncope associated with PAF. For the persistence of hypokalemia (K þ ¼ 2.9 mEq/L), in the Emergency Room of our Hospital, 40 mEq of potassium chloride was infused intravenously, which resulted in the restoration of sinus rhythm. The subsequent monitoring of serum potassium levels, the ECGs seriated in the following days and the ECG Holter were normal. For the severe adverse event, we decided to exclude the donor from further PBSCa.
Our case emphasizes the importance of monitoring and managing hypokalemia, a complication that receives less attention than hypocalcemia. 5 Hypokalemia is defined as a serum potassium concentration below 3.5 mEq/L and is considered severe if it is below 2.5 mEq/L or if the patient is symptomatic. 6 In two previous studies, performed in patients with hematologic malignancies undergoing PBSCa, the hypokalemia was reported in B50% of cases. 5, 7 In hematological patients, besides the PBSCa, the hypokalemia could be caused by different causes, including chemotherapy, parenteral nutrition, diarrhea, vomiting, renal tubule failure and diuretic therapy. 7 In the subset of healthy donors, the hypokalemia should generally be the direct consequence of PBSCa and as complication it is not usually reported. In fact, it has been verified that in 2408 unrelated donors the great majority of procedure-related side effects were represented by hypocalcemia, vasovagal reactions, bleeding secondary to anticoagulation and thrombocytopenia, and problems with venous access; hypokalemia or adverse cardiac events were not reported. 1 Only one very small prospective clinical and laboratory study (40 PBSC donors) showed minor changes in serum potassium without the need for hospitalization. 8 The pathogenesis of hypokalemia during PBSCa is unknown, and it may be due to the onset of mild alkalosis during the procedure or due to the metabolic processing of the dextrose or as a result of urinary loss. 5, 7 The citrate content in the ACD-A can participate in the Krebs tricarboxylic acid cycle, resulting in the production of three bicarbonate anions and the development of alkalosis. 7 The dextrose content in the ACD-A stimulates the release of insulin. 7 The metabolic alkalosis and the insulin induce the release of H þ from the cell and the entry of Na þ . There is now more Na þ in cells to be transported by Na þ / K þ -ATPase. 9 This can contribute to the development of hypokalemia. The hypokalemia determines in the cardiac muscle a decrease in conduction velocity, a shortening of the effective refractory period, a prolongation of the relative refractory period, an increased automaticity and early afterdepolarizations. 10 Hypokalemia-induced hyperexcitability is clinically manifested by an increase in supraventricular and ventricular ectopy. 10 In our case, we can exclude an excessive citrate toxicity, which may be due to the high ratio of ACD/weight and the large number of procedures, as well as to the female gender. 11 Our female donor underwent only one apheresis, and the ratio ACD/weight was equal to 10.8 mL/kg, well below the average of 14.21 reported in the study of Domnez. 11 Unfortunately, we cannot confirm that the alkalosis is caused by hypokalemia, nor can we quantify the urinary losses of potassium. The plasma pH measurements and the urinalysis post PBSCa are not known: these laboratory tests usually are not performed in healthy donors. 3, 4 Potassium supplementation is largely empirical and is guided by serum potassium levels. 6 Hypokalemia is treated by administering oral or i.v. potassium supplements. Intravenous potassium supplementation is reserved for the treatment of severe or symptomatic hypokalemia. 6 The response to the oral potassium repletion is generally delayed compared with i.v. repletion: oral potassium enters in circulation more slowly and the total daily dosage should be divided into two or four doses to avoid adverse gastrointestinal effects. 6 We treated the moderate hypokalemia with oral potassium; this was not sufficient to increase the serum potassium levels and to avoid the onset of the arrhythmia. Perhaps, the rapid development of moderate hypokalemia after PBSCa would have required a treatment with i.v. potassium in order to correct more quickly the hypokalemia, to reduce the risk of arrhythmia, to preserve the physical integrity of the healthy donor and to avoid low yield. Our recommendations are in accordance with those reported by other authors who leave the choice to the physician to administer potassium orally or intravenously. 5, 7 Donor stem cells for allogeneic transplant are traditionally collected immediately before transplant and transfused 'fresh' into the recipient on the day of transplant. The adverse event that occurred in our case calls into question this choice. It is known, however, that the use of cryopreserved stem cells is associated with a higher incidence of transfusion reactions and bacterial graft contamination. 12 We believe that a greater control and a more rapid correction of hypokalemia can also allow risks to the recipient to be avoided. However, in our case, a second female donor aged 61 years old and a rescue of the patient's stem cells were available.
